Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Back

ESC Premium Access

Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Session: New trends in antithrombotic therapy for atrial fibrillation

Topic: Atrial fibrillation (AF)

Speaker: Associate Professor C. Melloni (Durham, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Associate Professor Chiara Melloni

Cytokinetics, Durham (United States of America)

0 follower

8 more presentations in this session

Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.

Speaker: Doctor A. Banerjee (London, GB)

Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Speaker: Doctor M. Rao (Durham, US)

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Speaker: Doctor O. Yin (Edison, New Jersey, US)

Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.

Speaker: Miss S. Itainen-Stromberg (Helsinki, FI)

When should we start thromboprophylaxis? The stroke risk threshold discrepancy between European and U.S. guidelines for atrial fibrillation

Speaker: Mr P. Nielsen (Aalborg, DK)

Access the full session

New trends in antithrombotic therapy for atrial fibrillation

Speakers: Associate Professor C. Melloni, Doctor A. Banerjee, Doctor M. Rao, Doctor O. Yin, Miss S. Itainen-Stromberg...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources